SEMAX nothing more. nothing less.
SEMAX is a synthetic heptapeptide analog derived from ACTH (4–10). Studied in research involving BDNF upregulation, neurotrophic signaling, and cognitive performance pathways.
Purity >99%Form Lyophilized PowderNo Endotoxins
Order within
—
Notify me when back in stock
For research use only — not for human consumption, therapeutic, or diagnostic use. By adding to cart you acknowledge these terms.
Blank. Credentials
Institutional-grade credentials you can verify
About This Compound
Deep technical insights for clinical research
Primary Research Applications
This compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.
Upregulates BDNF and NGF expression in hippocampal and cortical tissue, supporting studies of synaptic plasticity and neurogenesis.
Modulates dopaminergic and serotonergic neurotransmission, with research applications in attention, memory, and cerebrovascular injury models.
Research Community Feedback
"Consistency is paramount in our cellular model testing. Blank's peptides have maintained the tightest purity specs of any RUO vendor we've audited."
Dr. Julian Kessler
Lead Investigator, Biomatrix Labs
"The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification. Professional grade synthesis."
Anika S. Singh
Synthetics Quality Control
"Finally, a supplier that doesn't hide behind consumer marketing. Stark, clear, and high-purity. Exactly what a modern lab needs."
Prof. David Emmerich
Applied Peptide Research
Complete The Protocol
Pairs & Supplies
The compounds and tools researchers stack with SEMAX.
Peer-Reviewed Literature
Related Studies
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial)
New England Journal of Medicine
Landmark trial of 17,604 patients showed semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% in non-diabetic patients with obesity over 39.8 months.
Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes (SUSTAIN-6)
New England Journal of Medicine
104-week trial in 3,297 high-risk T2DM patients showed semaglutide reduced composite MACE by 26% versus placebo — establishing cardiovascular benefit for GLP-1 receptor agonists.
Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes (PIONEER 6)
New England Journal of Medicine
Demonstrated cardiovascular safety of oral semaglutide 14 mg daily versus placebo in 3,183 high-risk T2DM patients, with trend toward all-cause mortality reduction.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
New England Journal of Medicine
68-week trial of 1,961 adults showed semaglutide 2.4 mg weekly achieved 14.9% mean body weight loss versus 2.4% with placebo, establishing landmark weight management efficacy.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
New England Journal of Medicine
In 3,297 patients with T2D, semaglutide reduced major adverse cardiovascular events by 26% versus placebo over 2.1 years (HR 0.74), driven by 39% stroke reduction and 26% nonfatal MI reduction.
Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Nature Medicine
Participants receiving semaglutide 2.4 mg weekly maintained 15.2% body weight loss at 104 weeks, with significant improvements in cardiometabolic risk factors including waist circumference and HbA1c.